The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer

被引:0
作者
J E M Crozier
R F McKee
C S McArdle
W J Angerson
J H Anderson
P G Horgan
D C McMillan
机构
[1] Royal Infirmary,University Department of Surgery
来源
British Journal of Cancer | 2006年 / 94卷
关键词
C-reactive protein; albumin; Dukes stage; 5-FU adjuvant chemotherapy; survival; colorectal cancer;
D O I
暂无
中图分类号
学科分类号
摘要
There is increasing evidence that the presence of a systemic inflammatory response plays an important role in survival following curative resection for colorectal cancer. The present study evaluated the relationship between C-reactive protein concentrations and survival in a cohort of patients receiving adjuvant 5-fluorouracil (5-FU) chemotherapy following potentially curative resection for colorectal cancer. In all, 222 patients undergoing potentially curative resection for colorectal cancer were studied. Of these, 50 patients received adjuvant 5-FU-based chemotherapy. Circulating concentrations of C-reactive protein were measured prior to surgery. The minimum follow-up was 15 months; the median follow-up of the survivors was 38 months. During this period 61 patients died, 32 patients of their cancer and 29 of intercurrent disease. In those patients who did not receive adjuvant chemotherapy, age (P<0.001), Dukes stage (P<0.05) and an elevated C-reactive protein (P<0.01) were significantly associated with survival. In those patients who did receive adjuvant chemotherapy, an elevated C-reactive protein concentration (P<0.01) was significantly associated with survival. The presence of a systemic inflammatory response is an independent predictor of poor outcome in patients receiving adjuvant 5-FU-based chemotherapy following potentially curative resection for colorectal cancer.
引用
收藏
页码:1833 / 1836
页数:3
相关论文
共 135 条
[1]  
Andreyev HJ(1998)Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34 503-509
[2]  
Norman AR(2004)Factors affecting cytochrome P-450 3A activity in cancer patients Clin Cancer Res 10 8341-8350
[3]  
Oates J(2004)American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer J Clin Oncol 22 3408-3419
[4]  
Cunningham D(2004)The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer Br J Cancer 91 1236-1238
[5]  
Baker SD(2005)The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer Br J Cancer 92 651-654
[6]  
van Schaik RH(2003)Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors Ann Oncol 14 ii25-ii29
[7]  
Rivory LP(2001)Acute phase response during radiotherapy Int J Radiat Oncol Biol Phys 49 1093-1096
[8]  
Ten Tije AJ(1958)The spread of rectal cancer and its effect on prognosis Br J Cancer 12 309-320
[9]  
Dinh K(2004)Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer Br J Cancer 90 1704-1706
[10]  
Graveland WJ(1987)A new prognostic classification of rectal cancer Lancet 1 1303-1306